DK1144001T3 - Inaktiveret influenzavirusvaccine til nasal eller oral indgivelse - Google Patents
Inaktiveret influenzavirusvaccine til nasal eller oral indgivelseInfo
- Publication number
- DK1144001T3 DK1144001T3 DK00903423T DK00903423T DK1144001T3 DK 1144001 T3 DK1144001 T3 DK 1144001T3 DK 00903423 T DK00903423 T DK 00903423T DK 00903423 T DK00903423 T DK 00903423T DK 1144001 T3 DK1144001 T3 DK 1144001T3
- Authority
- DK
- Denmark
- Prior art keywords
- influenza virus
- nasal
- oral administration
- inactivated influenza
- virus vaccine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/542—Mucosal route oral/gastrointestinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55544—Bacterial toxins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/82—Proteins from microorganisms
- Y10S530/826—Viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AT0019499A AT407958B (de) | 1999-02-11 | 1999-02-11 | Inaktivierte influenza-virus-vakzine zur nasalen oder oralen applikation |
PCT/AT2000/000023 WO2000047222A2 (fr) | 1999-02-11 | 2000-02-01 | Vaccin a virus grippal inactive pour application nasale ou orale |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1144001T3 true DK1144001T3 (da) | 2008-09-15 |
Family
ID=3483987
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK00903423T DK1144001T3 (da) | 1999-02-11 | 2000-02-01 | Inaktiveret influenzavirusvaccine til nasal eller oral indgivelse |
Country Status (10)
Country | Link |
---|---|
US (4) | US6635246B1 (fr) |
EP (1) | EP1144001B1 (fr) |
AT (2) | AT407958B (fr) |
AU (1) | AU770923B2 (fr) |
CY (1) | CY1108272T1 (fr) |
DE (1) | DE50015170D1 (fr) |
DK (1) | DK1144001T3 (fr) |
ES (1) | ES2307494T3 (fr) |
PT (1) | PT1144001E (fr) |
WO (1) | WO2000047222A2 (fr) |
Families Citing this family (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK1086207T3 (da) * | 1998-06-12 | 2007-05-29 | Sinai School Medicine | Hidtil ukendte fremgangsmåder og inteferon-deficiente substrater til opformering af vira |
AT407958B (de) * | 1999-02-11 | 2001-07-25 | Immuno Ag | Inaktivierte influenza-virus-vakzine zur nasalen oder oralen applikation |
BR0014281A (pt) * | 1999-09-24 | 2002-05-21 | Smithkline Beecham Biolog | Vacina contra vìrus de gripe intranasal |
GB9923176D0 (en) * | 1999-09-30 | 1999-12-01 | Smithkline Beecham Biolog | Novel composition |
US9974847B2 (en) * | 2000-08-24 | 2018-05-22 | Immunitor USA, Inc. | Treatment and prevention of tuberculosis |
US20030092145A1 (en) * | 2000-08-24 | 2003-05-15 | Vic Jira | Viral vaccine composition, process, and methods of use |
CA2545325C (fr) * | 2003-11-10 | 2015-01-13 | Uab Research Foundation | Compositions permettant de reduire le portage bacterien et l'invasion bacterienne du snc et methodes d'utilisation de ces compositions |
US20080254065A1 (en) | 2004-03-09 | 2008-10-16 | Chiron Corporation | Influenza Virus Vaccines |
EP3332803B1 (fr) | 2004-06-01 | 2021-09-08 | Icahn School of Medicine at Mount Sinai | Virus de la grippe porcine génétiquement modifié et ses utilisations |
US8137676B2 (en) * | 2005-02-15 | 2012-03-20 | Mount Sinai School Of Medicine | Genetically engineered equine influenza virus and uses thereof |
US20090081253A1 (en) | 2005-03-23 | 2009-03-26 | Glaxosmithkline Biologicals S.A. | Composition |
NZ595736A (en) | 2005-12-02 | 2013-05-31 | Sinai School Medicine | Chimeric viruses presenting non-native surface proteins and uses thereof |
MX2009000660A (es) | 2006-07-17 | 2009-04-08 | Glaxosmithkline Biolog Sa | Vacuna de influenza. |
MX2009001778A (es) * | 2006-08-17 | 2009-05-22 | Uab Research Foundation | Peptidos pcpa inmunogenicos y usos de los mismos. |
US20080124355A1 (en) | 2006-09-22 | 2008-05-29 | David Gordon Bermudes | Live bacterial vaccines for viral infection prophylaxis or treatment |
TW200908994A (en) | 2007-04-20 | 2009-03-01 | Glaxosmithkline Biolog Sa | Vaccine |
CN101688194B (zh) * | 2007-05-23 | 2013-09-11 | Uab研究基金会 | 去毒的肺炎球菌神经氨酸酶及其用途 |
KR100850545B1 (ko) * | 2007-10-30 | 2008-08-05 | 주식회사 에니멀제네틱스 | 신규한 개 인플루엔자 바이러스 및 이의 백신 |
CA2721800A1 (fr) * | 2008-04-21 | 2009-10-29 | Nanobio Corporation | Vaccin antigrippal a base de nanoemulsion |
US8647642B2 (en) | 2008-09-18 | 2014-02-11 | Aviex Technologies, Llc | Live bacterial vaccines resistant to carbon dioxide (CO2), acidic PH and/or osmolarity for viral infection prophylaxis or treatment |
WO2010077986A2 (fr) | 2008-12-16 | 2010-07-08 | Baxter International Inc. | Production de vaccins viraux |
CN101524537B (zh) * | 2009-03-26 | 2012-11-28 | 成都康华生物制品有限公司 | 流感口服含片疫苗、流感口服缓释疫苗以及二者制备方法 |
WO2010117786A1 (fr) | 2009-03-30 | 2010-10-14 | Mount Sinai School Of Medicine Of New York University | Vaccins pour le virus influenza et leurs utilisations |
US9907746B2 (en) | 2009-07-06 | 2018-03-06 | Variation Biotechnologies, Inc. | Methods for preparing vesicles and formulations produced therefrom |
MX2012000372A (es) | 2009-07-06 | 2012-02-28 | Variation Biotechnologies Inc | Metodos para preparar vesiculas y formulaciones producidas a partir de las mismas. |
US9217157B2 (en) | 2009-07-27 | 2015-12-22 | Icahn School Of Medicine At Mount Sinai | Recombinant influenza viruses and uses thereof |
WO2011014645A1 (fr) | 2009-07-30 | 2011-02-03 | Mount Sinai School Of Medicine Of New York University | Virus de la grippe et leurs utilisations |
US20110110975A1 (en) * | 2009-11-06 | 2011-05-12 | Streck, Inc. | Inactivated virus compositions and methods of preparing such compositions |
US9540420B2 (en) * | 2010-03-02 | 2017-01-10 | Tokushima University | Mucosal vaccines |
KR20130075732A (ko) | 2010-03-30 | 2013-07-05 | 마운트 시나이 스쿨 오브 메디슨 | 인플루엔자 바이러스 백신 및 이의 용도 |
JP6119030B2 (ja) | 2010-07-06 | 2017-04-26 | ヴァリエーション バイオテクノロジーズ インコーポレイテッド | インフルエンザを治療するための組成物及び方法 |
US20130323280A1 (en) | 2011-01-13 | 2013-12-05 | Variation Biotechnologies, Inc. | Methods for preparing vesicles and formulations produced therefrom |
EP2663327A4 (fr) | 2011-01-13 | 2015-12-02 | Variation Biotechnologies Inc | Compositions et méthodes de traitement d'infections virales |
WO2012151391A2 (fr) | 2011-05-04 | 2012-11-08 | Streck, Inc. | Compositions virales inactivées et leurs procédés de préparation |
CA2840982C (fr) | 2011-07-06 | 2022-06-07 | Vira BITKO | Vaccin contre le virus syncytial respiratoire humain |
US20130189303A1 (en) | 2011-08-02 | 2013-07-25 | Yan Zhou | Recombinant swine influenza virus and uses thereof |
CA2845872C (fr) | 2011-08-22 | 2023-03-28 | Nanobio Corporation | Vaccin contre le virus de l'herpes simplex sous forme de nanoemulsion |
AU2012312529B2 (en) | 2011-09-20 | 2018-01-04 | Icahn School Of Medicine At Mount Sinai | Influenza virus vaccines and uses thereof |
EP2780350B1 (fr) | 2011-11-18 | 2019-03-06 | Variation Biotechnologies Inc. | Dérivés synthétiques de mpl et ses utilisations |
AU2013208693B2 (en) | 2012-01-12 | 2017-12-07 | Variation Biotechnologies Inc. | Compositions and methods for treating viral infections |
CA2894467A1 (fr) | 2012-01-27 | 2013-08-01 | Variation Biotechnologies Inc. | Procedes de preparation de compositions thermostables comprenant un compose lipidique et des agents therapeutiques thermolabiles |
WO2014099931A1 (fr) | 2012-12-18 | 2014-06-26 | Icahn School Of Medicine At Mount Sinai | Vaccins contre le virus de la grippe et leurs utilisations |
WO2014164699A1 (fr) * | 2013-03-11 | 2014-10-09 | The Regents Of The University Of California | Vaccins et traitements contre le virus de l'herpès |
WO2014159960A1 (fr) | 2013-03-14 | 2014-10-02 | Icahn School Of Medicine At Mount Sinai | Anticorps contre l'hémagglutinine du virus de la grippe et utilisations correspondantes |
US9616114B1 (en) | 2014-09-18 | 2017-04-11 | David Gordon Bermudes | Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity |
CA2974699A1 (fr) | 2015-01-23 | 2016-07-28 | Icahn School Of Medicine At Mount Sinai | Regimes de vaccination contre le virus de la grippe |
AU2016222962B2 (en) | 2015-02-26 | 2020-05-21 | Boehringer Ingelheim Vetmedica Gmbh | Bivalent swine influenza virus vaccine |
BR112018075032A2 (pt) | 2016-06-15 | 2019-03-26 | Icahn School Of Medicine At Mount Sinai | proteínas de hemaglutinina do vírus influenza e seus uso |
US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
EP3606555A4 (fr) | 2017-04-07 | 2021-08-04 | Icahn School of Medicine at Mount Sinai | Anticorps anti-neuraminidase du virus influenza de type b et leurs utilisations |
US11471497B1 (en) | 2019-03-13 | 2022-10-18 | David Gordon Bermudes | Copper chelation therapeutics |
WO2021069543A1 (fr) | 2019-10-08 | 2021-04-15 | Luxembourg Institute Of Health (Lih) | Inhibiteur de dj-1 destiné à être utilisé dans le traitement de l'immunosénescence |
US10973908B1 (en) | 2020-05-14 | 2021-04-13 | David Gordon Bermudes | Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS62201574A (ja) * | 1986-02-27 | 1987-09-05 | Shionogi & Co Ltd | 家禽用インフルエンザワクチン |
US4981782A (en) * | 1987-05-14 | 1991-01-01 | Sri International | Synthetic peptides for diagnosis and prevention of influenza virus infection and their use |
US5136019A (en) * | 1989-05-24 | 1992-08-04 | Sri International | Synthetic peptides for diagnosis and prevention of influenza virus infection and their use |
US5243030A (en) * | 1989-05-24 | 1993-09-07 | Sri International | Conjugates of a synthetic peptide for diagnosis and prevention of influenza virus infection |
AU6141094A (en) * | 1993-02-19 | 1994-09-14 | Smithkline Beecham Biologicals (Sa) | Influenza vaccine compositions containing 3-o-deacylated monophosphoryl lipid a |
US5562909A (en) * | 1993-07-12 | 1996-10-08 | Massachusetts Institute Of Technology | Phosphazene polyelectrolytes as immunoadjuvants |
US5976552A (en) * | 1995-04-28 | 1999-11-02 | Protein Sciences Corporation | Virus vaccines |
DK0791055T3 (da) * | 1994-11-10 | 2012-04-16 | Baxter Healthcare Sa | Fremgangsmåde til fremstilling af biologiske produkter i proteinfri kultur |
US6949244B1 (en) * | 1995-12-20 | 2005-09-27 | The Board Of Trustees Of The University Of Kentucky | Murine monoclonal anti-idiotype antibody 11D10 and methods of use thereof |
US5690942A (en) * | 1995-06-02 | 1997-11-25 | American Home Products Corporation | Adjuvants for viral vaccines |
US6251405B1 (en) | 1995-06-07 | 2001-06-26 | Connaught Laboratories, Inc. | Immunological combination compositions and methods |
US5989805A (en) | 1995-10-27 | 1999-11-23 | Board Of Trustees Operating Michigan State University | Immortal avian cell line to grow avian and animal viruses to produce vaccines |
US5919480A (en) * | 1996-06-24 | 1999-07-06 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Liposomal influenza vaccine composition and method |
AT408615B (de) * | 1998-09-15 | 2002-01-25 | Immuno Ag | Neue influenzavirus-impfstoffzusammensetzung |
AT407958B (de) * | 1999-02-11 | 2001-07-25 | Immuno Ag | Inaktivierte influenza-virus-vakzine zur nasalen oder oralen applikation |
-
1999
- 1999-02-11 AT AT0019499A patent/AT407958B/de not_active IP Right Cessation
-
2000
- 2000-02-01 ES ES00903423T patent/ES2307494T3/es not_active Expired - Lifetime
- 2000-02-01 US US09/913,400 patent/US6635246B1/en not_active Expired - Lifetime
- 2000-02-01 PT PT00903423T patent/PT1144001E/pt unknown
- 2000-02-01 DK DK00903423T patent/DK1144001T3/da active
- 2000-02-01 WO PCT/AT2000/000023 patent/WO2000047222A2/fr active IP Right Grant
- 2000-02-01 EP EP00903423A patent/EP1144001B1/fr not_active Expired - Lifetime
- 2000-02-01 AT AT00903423T patent/ATE395929T1/de active
- 2000-02-01 DE DE50015170T patent/DE50015170D1/de not_active Expired - Lifetime
- 2000-02-01 AU AU25253/00A patent/AU770923B2/en not_active Expired
-
2003
- 2003-08-13 US US10/639,449 patent/US6861244B2/en not_active Expired - Lifetime
-
2005
- 2005-01-04 US US11/027,936 patent/US7052701B2/en not_active Expired - Lifetime
-
2006
- 2006-03-02 US US11/365,836 patent/US20060147468A1/en not_active Abandoned
-
2008
- 2008-08-20 CY CY20081100884T patent/CY1108272T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
DE50015170D1 (de) | 2008-07-03 |
AU770923B2 (en) | 2004-03-11 |
EP1144001A2 (fr) | 2001-10-17 |
ATE395929T1 (de) | 2008-06-15 |
AU2525300A (en) | 2000-08-29 |
US20040096464A1 (en) | 2004-05-20 |
US6635246B1 (en) | 2003-10-21 |
EP1144001B1 (fr) | 2008-05-21 |
CY1108272T1 (el) | 2014-02-12 |
ES2307494T3 (es) | 2008-12-01 |
AT407958B (de) | 2001-07-25 |
US20050196413A1 (en) | 2005-09-08 |
US6861244B2 (en) | 2005-03-01 |
WO2000047222A2 (fr) | 2000-08-17 |
PT1144001E (pt) | 2008-08-29 |
ATA19499A (de) | 2000-12-15 |
US7052701B2 (en) | 2006-05-30 |
US20060147468A1 (en) | 2006-07-06 |
WO2000047222A3 (fr) | 2001-10-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1144001T3 (da) | Inaktiveret influenzavirusvaccine til nasal eller oral indgivelse | |
MX9702336A (es) | Composiciones de vacuna. | |
HUP0100058A1 (hu) | LTB Adjuvánst tartalmazó vakcinák | |
DK1216053T3 (da) | Influenzavaccine | |
DK1326636T3 (da) | Vaccinesammensætning | |
NZ323973A (en) | Vaccine compositions for intranasal administration comprising chitosan and use thereof | |
HUP9801560A1 (hu) | Szaponint és szterint tartalmazó vakcinák | |
BRPI0007936B8 (pt) | composto, formulação adjuvante imunológica, e formulação de vacina. | |
FI944676A0 (fi) | Rokotteita, jotka sisältävät ionisoitumattomia pinta-aktiivisten aineiden vesikkeleitä | |
ATE458496T1 (de) | Hiv-vakzine und anwendungsverfahren | |
Cusi et al. | Immunopotentiating of mucosal and systemic antibody responses in mice by intranasal immunization with HLT-combined influenza virosomal vaccine | |
JP2003514030A5 (fr) | ||
WO2001035993A3 (fr) | Compositions et methodes destines a stimuler une reponse immune contre des agents infectieux | |
GB1413401A (en) | Influenza vaccine |